^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Uterine Leiomyosarcoma
    Drug:pazopanib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...other single agent options...can also be considered for advanced or metastatic disease, including dacarbazine...pazopanib...